The unintended consequences of the inflation reduction act on biosimilar market incentives and Medicare savings
{{output}}
Introduction: The Inflation Reduction Act (IRA) authorizes Medicare price negotiation but includes a "special rule" deferring negotiation for biologics with "imminent" biosimilar competition. This study examined the potential... ...
